GHK-Cu for Inflammation: What the Evidence Shows
What human and animal studies show about GHK-Cu for inflammation, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- 13
- PubMed records, our ledger
- Animal studies
- 12
- PubMed records, our ledger
- Studies we summarised
- 3
- with an outcome for inflammation
Evidence for inflammation
Each row is an outcome related to inflammation from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Colitis severity and mucosal repair | GHK-Cu reduced weight loss, disease activity and colonic inflammatory damage and promoted mucosal repair in DSS colitis mice. | Animal · mouse (plus mouse cell co-culture) (not a human result) | Frontiers in pharmacology 2025, PMID 40672369 |
| Lung inflammation and fibrosis | GHK-Cu reduced lung inflammation and fibrosis in silicosis mice without significant systemic toxicity. | Animal · mouse (plus macrophage cell line) (not a human result) | Redox biology 2024, PMID 38879894 |
| Lung inflammation | GHK-Cu reduced lung histological changes and inflammatory cell infiltration in mice with acute lung injury. | Animal · mouse (plus macrophage cell line) (not a human result) | Oncotarget 2016, PMID 27517151 |
PubMed records for GHK-Cu and inflammation: 13 human, 12 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Inflammation, and the measure used to track it
MedlinePlus explains that the liver makes CRP in response to inflammation, which is why a blood test for it is used as an inflammation marker.[4]
The same page describes acute inflammation as a protective, helpful process and chronic inflammation as potentially damaging.[4]
What GHK-Cu studies measured that is closest to inflammation
In mice with lipopolysaccharide-induced acute lung injury, treatment cut TNF-α and IL-6 and reduced inflammatory cell infiltration of the lung.[3]
In mice with chemically induced colitis, treatment lowered several cytokines and promoted mucosal repair.[1]
In mice with silicosis, the complex reduced lung inflammation and fibrosis, linked to antioxidant effects in macrophages.[2]
The PubMed record count behind the inflammation ledger (2 Oct 2026): 63 records for GHK-Cu terms with inflammation, colitis, C-reactive protein or TNF words, of which 13 are human-only, 12 are animal-only and 0 are randomized controlled trials.
Calculated from ledger query GHK-Cu terms AND (inflammat*[tiab] OR colitis[tiab] OR "C-reactive protein"[tiab] OR "tumor necrosis factor"[tiab] OR "tumour necrosis factor"[tiab]); date 2026-10-02; all 63; human only 13; animal only 12; rct 0; source our PubMed count ledger inflammation / ghk-cu ledger. Formula: counts as recorded in the goals.json ledger; human-only = humans[mh] NOT animals[mh:noexp]
Safety data for people with inflammatory conditions
The silicosis study reports no significant systemic toxicity, but this was in mice and not in people with lung disease.[2]
Other peptides people research for inflammation
All peptides for inflammation, comparedCommon questions
Does GHK-Cu help with inflammation?
The strongest study we summarise for inflammation is animal evidence, across 3 studies with an outcome for inflammation. That is not proof it works in people.
Is GHK-Cu approved for inflammation?
No. GHK-Cu is not FDA approved for any use, including inflammation.
What is the best peptide for inflammation?
There is no single answer. Our inflammation overview compares each candidate by evidence grade and legal status rather than by popularity.
Does GHK-Cu reduce inflammation?
In mice and cell cultures it lowered TNF-α and IL-6; no human inflammation trial is cached.[3]
Has GHK-Cu been tested for ulcerative colitis in people?
The cached study used mice given 3% DSS for 14 days; it is a model, not a human trial.[1]
More on GHK-Cu
Sources
- 1Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.Frontiers in pharmacology · 2025PMID 40672369Accessed 2 Oct 2026
- 2The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.Redox biology · 2024PMID 38879894Accessed 2 Oct 2026
- 3The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice.Oncotarget · 2016PMID 27517151Accessed 2 Oct 2026
- 4Official web pageOfficial web page · web page
Found an error? Report a correction.